Home Recalls D-1309-2020
Class II · Moderate risk Terminated Initiated Jun 11, 2020 (6 years ago)
Irinotecan HCL Injection, USP, 100mg/5mL, 5 mL vials, Rx only, Manufactured by…
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.
What was recalled
Irinotecan HCL Injection, USP, 100mg/5mL, 5 mL vials, Rx only, Manufactured by: Thymoorgan Pharmazie GmbH, Shiffgraben 23, 38690 Golsar, Germany Distributed by: West-Word Pharmaceutical Corp. Eatontown, NJ 07724 USA, NDC 0143-9583-01
Recalling firm Hikma Pharmaceuticals USA Inc.
NDC code 0143-9583-01
Origin NJ, United States
Initiated by Voluntary: Firm initiated
FDA recall number D-1309-2020
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Class II · Moderate risk Terminated Nov 19, 2020
Reason CGMP Deviations: based on a Warning Letter received by the manufacturer of the recalled product for inadequate out-of specification investigations…
Class II · Moderate risk Terminated Jun 11, 2020
Reason Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.
Class II · Moderate risk Terminated Jun 12, 2019
Reason Lack of Assurance of Sterility
Class II · Moderate risk Terminated Jun 8, 2018
Reason Superpotent Drug: High out of specification assay value results for potency.
Class II · Moderate risk Terminated Jun 8, 2018
Reason Superpotent Drug: High out of specification assay value results for potency.